Anavex Presents Positive Initial Phase 2a Study Data with ANAVEX 2-73 showing Early Evidence of Improving Cognition in Patients with Alzheimer’s Disease at AAIC 2015
Anavex to Present Initial Clinical Data from the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer’s Association International Conference (AAIC)
Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer’s Disease
Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference
